Q-omics provides the consensus-scored PHKA2 profile across patient tissues and cancer cell-line models. PHKA2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PHKA2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PHKA2 RNA expression shows 19,675 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KICH, KIRC, and KIRP as cancer lineages where PHKA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHKA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHKA2 survival associations across molecular data types. PHKA2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHKA2 RNA expression–survival associations across cancer types. High PHKA2 expression shows unfavorable associations in KICH, LIHC and LGG, but favorable associations in UVM, THYM and BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for PHKA2 RNA expression.
This table summarizes PHKA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PHKA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHKA2 shows lower tumor expression in BRCA, THCA and KICH and higher tumor expression in KIRC, BLCA and STAD. The KIRC box plot shows higher PHKA2 RNA expression in tumor versus normal tissue (log2 FC = +2.386, t-test p < 0.001).
This table shows molecular features associated with PHKA2 in patient tissues and cancer cell lines. In patient samples, PHKA2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, PHKA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SOFT_TISSUE.
